Emergent BioSolutions (EBS) Income from Non-Controlling Interests (2011 - 2013)
Emergent BioSolutions (EBS) recorded quarterly Income from Non-Controlling Interests of -$5000.0 in Q4 2013, up 96.09% quarter-over-quarter from -$128000.0 in Q2 2013, and up 99.55% on a YoY basis from -$2505.7 in Q4 2012.
Emergent BioSolutions (EBS) Income from Non-Controlling Interests (2011 - 2013) Analysis & Trends
Emergent BioSolutions' Income from Non-Controlling Interests history runs 3 years deep, the most recent figure standing at -$5000.0 for Q4 2013.
- In Q4 2013, Income from Non-Controlling Interests rose 99.55% year-over-year to -$5000.0; the TTM figure through Sep 2014 stood at -$5000.0 (up 99.75% YoY), while the FY2013 annual figure was -$876000.0, up 83.72% from the prior year.
- Income from Non-Controlling Interests was -$5000.0 for Q4 2013 at Emergent BioSolutions, up from -$128000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$5000.0 in Q4 2013 to a low of -$2.1 million in Q2 2012.
- Historically, Income from Non-Controlling Interests has averaged -$1.1 million across 3 years, with a median of -$1.1 million in 2012.
- The sharpest annual moves came in 2012 and 2013: Income from Non-Controlling Interests retreated 23.65% in 2012, then surged 99.55% in 2013.
- A 3-year view of Income from Non-Controlling Interests shows it stood at -$1.8 million in 2011, then soared by 37.11% to -$1.1 million in 2012, then soared by 99.55% to -$5000.0 in 2013.
- The last three Income from Non-Controlling Interests figures came in at -$5000.0 (Q4 2013), -$128000.0 (Q2 2013), and -$743000.0 (Q1 2013), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | - |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Emergent BioSolutions | 412.09 Mn | 250.59 Mn | 84.10 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | -5,000.00 |
| Jun 30, 2013 | -128,000.00 |
| Mar 31, 2013 | -743,000.00 |
| Dec 31, 2012 | -1.11 Mn |
| Sep 30, 2012 | -997,000.00 |
| Jun 30, 2012 | -2.09 Mn |
| Mar 31, 2012 | -1.19 Mn |
| Dec 31, 2011 | -1.76 Mn |
| Sep 30, 2011 | -1.69 Mn |
| Jun 30, 2011 | -1.69 Mn |